Feeds:
Posts
Comments

Pharma News 3_22

Cephalon‘s Treanda approved for leukemia: Cephalon Inc. received clearance from regulators yesterday to begin selling Treanda as a treatment for a rare form of leukemia. The medicine will be a new option for about 15,000 people in the United States diagnosed annually with the slow-progressing form of leukemia known as chronic lymphocytic leukemia, or CLL.

The Frazer, Pa., biotech company said it hoped to make Treanda the foundation for a growing oncology business…

Takeda and Abbott split up TAP: Takeda Pharmaceutical Co, Japan’s biggest drug maker, plans to spend some $5 billion to buy out Abbott Laboratories Inc in their 50-50 U.S. venture, a source briefed on the matter said on Wednesday…

More drugmaker disclosure to be debated in a pending bill: f a drugmaker or device maker gives docs payments or gifts worth more than $25, they would be required to disclose the info on their web sites. The bill, known as the Physician Sunshine Act, or HR 5605, was introduced into Congress by two Democrats, Pete DeFazio of Oregon and Pete Stark of California, and serves as a companion to a Senate bill

Vytorin and Zetia prescriptions dropping dramatically: U.S. prescriptions for embattled cholesterol drugs Vytorin and Zetia dropped 13% in February from January levels, after a patient study raised questions about their effectiveness….plus, a write-up on the clinical study problems (ENHANCE) that brought it all about.

Spiriva – possible negative side effects. The U.S. Food and Drug Administration said late on Tuesday that a meta-analysis of past clinical trials showed Spiriva may increase the risk of stroke, although the risk assessment was not yet conclusive…

Retreating drug sales forces – There are signs that the sales-force arms race among drug makers is easing–a bit…

Device companies, doctors, and bribes…going after both the “demand” and “supply” sides.

Our Daily Meds – the latest book to take a critical look at the pharmaceutical industry. Pharmalot (blog) has an interview with the author.

About these ads

One Response

  1. [...] John Mack wrote an interesting post today onHere’s a quick excerptTakeda and Abbott split up TAP: Takeda Pharmaceutical Co, Japan’s biggest drug maker, plans to spend some $5 billion to buy out Abbott Laboratories Inc in their 50-50 US venture, a source briefed on the matter said on Wednesday… … Tags: Night, Pharma [...]



Comments are closed.

Follow

Get every new post delivered to your Inbox.

Join 27 other followers

%d bloggers like this: